Search Results
Jun 03, 2026, 09:23 ET ProBio and GCP ClinPlus Partner to Accelerate Clinical Trials in China
cell and gene therapy (CGT) CDMO services with GCP ClinPlus's robust capabilities in clinical trial execution and site management across China. The combined offering supports cutting-edge therapeutic modalities, including:In vivo CAR-TGene therapyCancer
More news about: ProBio Inc.
Jun 03, 2026, 09:16 ET Terapia de edição de bases de alta precisão demonstra eficácia duradoura sem VOCs e perfil de segurança favorável na doença falciforme
hemoglobina causado por mutações no gene da β-globina. Os pacientes podem apresentar anemia crônica, crises de dor recorrentes, infecções e danos progressivos aos órgãos, com casos graves se tornando fatais. Aproximadamente 3,5% da população global é portadora do gene da mutação falciforme e cerca de 300.000
More news about: CorrectSequence Therapeutics
Jun 03, 2026, 09:16 ET Hochpräzise Basen-Editierungstherapie zeigt dauerhafte VOC-freie Wirksamkeit und günstige Sicherheit bei Sichelzellanämie
Hämoglobinopathien eingestuft, die weltweit zu den häufigsten monogenen Erbkrankheiten gehören. Etwa 7 % der Weltbevölkerung tragen abnorme Hämoglobin-Gene in sich, und jährlich werden weltweit schätzungsweise 400.000 betroffene Kinder geboren.Basierend auf der gleichen tBE-Technologieplattform und
More news about: CorrectSequence Therapeutics
Jun 03, 2026, 09:05 ET Une thérapie de réécriture de base de haute précision démontre une efficacité durable, sans crises vaso-occlusives et un profil d'innocuité favorable dans le traitement de la drépanocytose
mutations dans le gène de la β-globine. Les patients peuvent souffrir d'anémie chronique, de crises douloureuses récurrentes, d'infections et de lésions organiques progressives, les cas les plus graves pouvant mettre la vie en danger. Environ 3,5 % de la population mondiale est porteuse du gène de la drépanocytose
More news about: CorrectSequence Therapeutics
Jun 03, 2026, 08:30 ET Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
Information. About PWSPrader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The defining symptom
More news about: Neurocrine Biosciences, Inc.
Jun 03, 2026, 08:00 ET IDefine and UT Southwestern Announce Research Collaboration to Advance Gene Therapy for Rare Disease Kleefstra Syndrome
Steven Gray, PhD, professor at UT Southwestern and director of the UTSW Gene Therapy Program, will evaluate the feasibility and safety of EHMT1 gene replacement therapy using next-generation gene delivery technology designed to target the central nervous system (CNS)."This landmark
More news about: IDefine - The Kleefstra Syndrome Foundation
Jun 03, 2026, 08:00 ET Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant
More news about: Actinium Pharmaceuticals, Inc.
Jun 03, 2026, 07:25 ET Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant
More news about: Actinium Pharmaceuticals, Inc.
Jun 03, 2026, 07:00 ET Ascidian and Lilly Enter Global Research Collaboration to Develop RNA Exon Editors for Devastating Kidney Diseases
genome or introducing foreign enzymes — Ascidian's RNA exon editors are designed to combine the durability of gene therapy while sharply reducing risks associated with direct DNA editing and gene replacement in these conditions.About Ascidian TherapeuticsAscidian Therapeutics is redefining
More news about: Ascidian Therapeutics
Jun 03, 2026, 03:39 ET ACROBiosystems, 바이오 코리아 2026에서 GMP 역량 기반의 포괄적인 CGT 솔루션 선보이며 혁신 주도 및 파트너 역량 강화
전용 세션에서 ACROBiosystems는 세포 및 유전자 치료(Cell and Gene Therapy, CGT) 개발을 위한 포괄적인 엔드투엔드 솔루션을 선보였다. Resilient Supply™는 성장 인자와 무혈청 배지부터 생분해성 나노마그네틱 비드까지 다양한 GMP 등급 핵심 원자재를 제공하여 다양한 면역세포 및 줄기세포의 효율적인 배양과 분화를
More news about: ACROBiosystems
Jun 02, 2026, 18:44 ET NAVC Named to Inc.'s 2026 Best Workplaces List
"A happy team is a high-performing one, and at NAVC, we believe in creating environments where everyone can thrive," said Gene O'Neill, NAVC CEO. "Our culture is centered on the team, which naturally unlocks potential. We host open forums where employees share ideas and feedback,
More news about: North American Veterinary Community (NAVC)
Jun 02, 2026, 09:31 ET AvenCell Therapeutics to Report Phase 1a Results of First-in-Class Switchable Allogeneic CD123 CAR-T Therapy for AML in Late-Breaking oral presentation at EHA 2026
TopicGene therapy, cellular immunotherapy and vaccination - Clinical
More news about: AvenCell Therapeutics, Inc.
Jun 02, 2026, 09:05 ET Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
conducted by Vanderbilt Health investigators using the BioVU biorepository, which linked a naturally occurring genetic variant in the thromboxane receptor gene (TBXA2R) to an increased risk of metastatic disease across multiple cancer types.Preclinical studies subsequently published in Molecular Cancer
More news about: Cumberland Pharmaceuticals Inc.
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
spectrum. The company develops allogeneic, iPSC-derived NK and engineered immune-cell therapies — including a CAR-iNK candidate — using a proprietary gene-editing approach designed to help the cells evade host rejection. With cash and investments reported around $117 million at the end of 2025, bolstered
More news about: USA News Group
Jun 02, 2026, 08:39 ET Consumer Intelligence Firm Audiense Adds Senior Leaders as it Positions for Growth
(who led Cortera through a growth journey that resulted in its acquisition by Moody's Analytics in 2021), experienced CTO Liz Devine, and AI Strategist Gene Schoepp, the company has spent the past year integrating three complementary businesses — Audiense, Buxton, and Elevar — and creating a proprietary
More news about: Audiense
Jun 02, 2026, 08:00 ET Origin Agritech Co-Authors Plant Biotechnology Journal Study That Breaks the Long-Standing Trade-Off Between Early-Maturing and High-Yield Corn
come at a yield cost.Rather than deactivating the gene, the researchers used CRISPR/Cas9 gene-editing technology to make precise changes to the gene's regulatory "switches"—the surrounding stretches of DNA that determine where and when the gene is active in the plant. The edits selectively reduced
More news about: Origin Agritech Limited
Jun 02, 2026, 08:00 ET Converge Bio Secures $2.5M Grant to expand its fast-track AI gene discovery capabilities from pharma to growing climate-resilient crops
millions of base pairs simultaneously to identify genetic variants associated with climate resilience. Researchers can enter a section of DNA and related gene activity data, and the system will rank the genes or mutations most likely driving a specific outcome. It can also show which parts of the DNA led to
More news about: Converge Bio
Jun 02, 2026, 08:00 ET Kemp Proteins Selected by Avivo Biomedical to Support Process Optimization for Universal Blood Technology Program
Kemp Proteins is a biomanufacturing company specializing in recombinant protein production, protein engineering, cell line development, and accelerated gene-to-protein workflows. Through advanced expression systems, machine learning-driven optimization, and scalable bioprocess development, Kemp Proteins
More news about: Kemp Proteins
Jun 02, 2026, 07:00 ET Solid Biosciences and NanoMosaic Announce Co-Marketing Agreement to Advance Gene Therapy Delivery and Analytics
higher-confidence analytical foundation for gene therapy development.NanoMosaic's approach is supported by key opinion leaders in gene therapy, including Guangping Gao, a globally recognized AAV pioneer and former President of the American Society of Gene & Cell Therapy, who has emphasized the
More news about: NanoMosaic
Jun 02, 2026, 04:00 ET AbbVie Announces European Commission Approval of AQUIPTA® (atogepant) for the Acute Treatment of Migraine in Adults
adults with or without aura, to be taken as needed (PRN). This approval is the second indication in the European Union for AQUIPTA, an oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), which is now approved as both an acute treatment option for migraine attacks in adults and as a
More news about: AbbVie
Jun 02, 2026, 00:54 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
caused by mutations in the β-globin gene. Patients may experience chronic anemia, recurrent pain crises, infections, and progressive organ damage, with severe cases becoming life-threatening. Approximately 3.5% of global population carries the sickle cell mutation gene, and around 300,000 babies are born
More news about: CorrectSequence Therapeutics
Jun 02, 2026, 00:50 ET High-Precision Base-Editing Therapy Demonstrates Durable VOC-Free Efficacy and Favorable Safety in Sickle Cell Disease
caused by mutations in the β-globin gene. Patients may experience chronic anemia, recurrent pain crises, infections, and progressive organ damage, with severe cases becoming life-threatening. Approximately 3.5% of global population carries the sickle cell mutation gene, and around 300,000 babies are born
More news about: CorrectSequence Therapeutics
Jun 01, 2026, 16:50 ET Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit
More news about: Pacira BioSciences, Inc.
Jun 01, 2026, 10:00 ET Endeavor Health researchers develop more comprehensive genetic screening for heart disease risk
optimal health for individual patients and their family members.For more information and to determine eligibility for PRS testing, call 847-570-GENE. PRS testing is not currently covered by insurance companies. To learn more about the clinical study, please call 847-503-6402.About Endeavor
More news about: Endeavor Health
Jun 01, 2026, 08:31 ET The Evolving EGFR NSCLC Market: 8 Emerging Late-stage Therapies to Watch | DelveInsight
said that the market is witnessing a convergence of multiple advanced therapeutic platforms, including TKIs, ADCs, bispecific antibodies, CDACs, and gene therapy-based combinations. This expanding competitive landscape suggests that future market leadership will depend heavily on differentiation across
More news about: DelveInsight Business Research, LLP